Why healthtech positioning is different.

Most positioning advice was written for companies selling into markets that behave like markets. Buyers have budget. Budget has a calendar. Decisions have owners. Deals close when the math works. Healthtech is not that market. It has a dominant platform that most of your customers live inside, a buying committee that changes shape by health system, a procurement function that treats every new vendor as a risk event, and an inertia default that beats most competitors on most deals. You cannot apply April Dunford’s playbook directly. You cannot apply Andy Raskin’s playbook directly. They still matter, but the reality of the market comes first, and positioning that ignores it is positioning that does not survive security review.

I have been CRO and CMO inside this market. I have carried the number and owned the narrative. I currently sit on the board of a healthtech company, and I have also sat on the board of a pre-IPO healthtech company, which means I have seen the same pattern from the side that approves investment, replaces leaders, and writes down valuations when results do not materialize. What follows is what I have seen repeat, the pattern underneath the noise of any individual deal, pitch, or launch. If you are running GTM at a healthtech company and your pipeline is doing less than you thought it would, some of this will feel familiar.

One.Epic and Oracle are the environment, not traditional competitors.

The first thing to accept is that Epic and Oracle are not peers on a vendor slide. They are the gravitational field everything else orbits. Most of your buyers already live inside one of them. Their workflows, their identities, their reporting, their governance, and their switching costs are all denominated in that platform. When Epic ships a “good enough” version of something, the health system uses it, not because it is better, but because it is already there, already integrated, already paid for, and already governed.

This has one hard implication for positioning. Feature-level differentiation against Epic is fragile. You do not have to be worse to lose; you only have to be close enough that the switching cost is not worth it. The places you can build something durable are the places Epic structurally will not go: specialty depth that a horizontal platform will not prioritize, operations upstream of the EHR workflow, cross-system data that requires pulling from non-Epic sources, enterprise governance that point solutions cannot handle, and software-plus-services playbooks that create institutional knowledge Epic cannot replicate.

The question I ask every founder at the fit call: if Epic shipped a version of this next year, would your customers still need you? If the answer is no, you do not have durable differentiation. You have a head start. That is a different thing and it is priced differently by investors and acquirers.

Two.Anchor to one budget owner, even when you are selling to many.

Health systems have committees. You will need to message to several people to win a deal: IT, clinical leadership, finance, procurement, sometimes legal. But your positioning needs a single anchor: the economic buyer whose budget funds the decision. The CFO, the VP of RCM, the CIO, the CMO, the CNO, the VP of Access. Pick one. If your positioning speaks to three of them simultaneously it will be vague enough to land with none.

This is where most founders hedge. The hedge is understandable, because health system politics punish vendors who appear to bypass stakeholders, but the hedge is also the reason the pitch does not cut. Positioning is strategic; messaging is how you translate the position for different audiences along the way. The CMIO gets a different conversation than the CFO. Both should trace back to the same underlying logic, and that logic is anchored to the person who signs the check.

If you cannot name which single person owns the budget for your solution, your positioning is hypothetical.

Every budget owner tracks a specific set of metrics they are measured on. CFOs live in net revenue, denial rates, and days in AR. VP of Access lives in fill rate, time-to-appointment, and leakage. CMIOs live in workflow burden and integration governance. Research ops lives in enrollment velocity. If you cannot state your value in the exact metric your anchor buyer is already being measured on, you are not positioned. You are pitching. Those are different things, and the buyer knows which one they are being subjected to.

Three.Your biggest competitor is doing nothing.

In provider IT, the most common procurement outcome is not that a competitor wins. It is that the health system decides not to decide. Inertia wins more deals than any vendor. I have watched well-qualified pipelines evaporate in Q4 because governance did not meet, because the sponsoring VP took a new job, because IT was absorbed by an Epic upgrade, or because the champion could not get the security review scheduled. None of those reasons appear on your competitive slide. All of them are the actual competitor.

This happens because buying something new carries institutional risk. IT projects that drag on. Clinical workflows that get disrupted. Governance questions that nobody wants to own. If your positioning does not directly reduce that perceived risk, you are leaving the door open for inertia to win. The positioning needs to answer five questions the buyer is silently asking: how long until we see results, how much will this burden our IT team, who owns this operationally after go-live, how do we explain this to the governance committee, and what happens if it does not work.

“Live in eight weeks with no IT project required” is not a sales detail. It is a positioning statement, because it addresses the reason most deals die. Most founders treat implementation, governance readiness, and security posture as post-sale concerns. In healthtech they are the front of the sale. The ones who treat them that way close. The ones who do not watch deals go quiet in September and call it a budget problem.

Four.“Only” claims must survive security review.

Being the only something is more defensible than being the best something. Best is comparative and fragile; someone can always out-claim you. Only draws a categorical boundary. But in provider markets, “only” claims have a higher bar than in other B2B markets. They have to survive the specific scrutiny of enterprise IT, security, and legal review. Generic AI claims do not hold up. Vague category names do not hold up. If your “only” depends on language that a dozen competitors also use in their decks, it is not an “only.”

Strong “only” frames in this market share three traits: they are specific about the workflow, specific about the buyer, and specific about the constraint. Only Epic-native denial prevention that operates inside the claim workflow before submission. Only specialty-specific clinical documentation built for oncology practices over 200 providers. Only cross-system data intelligence that survives a health system’s enterprise governance review. These claims are narrow enough to be credible and structured enough to be defended when a skeptical CIO’s team pulls them apart.

Narrow feels risky to founders. It feels safer to buyers. Procurement hates ambiguity. Narrow scope simplifies stakeholder alignment, accelerates security review, makes ROI calculation straightforward, and gives your internal champion something they can actually sell inside the organization. Broad positioning does not feel safer to buyers; it feels riskier, because the scope and the ownership are unclear.

Five.Political alignment is positioning work.

Health systems are political institutions with established power structures. This is the dimension most positioning frameworks ignore entirely, and it is the dimension that kills the most deals in the second half of the sales cycle. Your positioning has to avoid threatening powerful departments, especially the CMO, CNO, and incumbent IT vendors, and has to avoid triggering turf wars between clinical and operational leadership.

If your value proposition creates internal losers, someone who looks bad, someone who loses budget, someone who loses authority, adoption stalls regardless of clinical or economic merit. I have watched products with documented outcomes die in committee because they made an incumbent vendor look foolish, or because the CMO’s team read them as a referendum on clinical workflow they had designed. The product did not change. The positioning failed to neutralize the politics.

This shows up in concrete ways. Do you frame yourself as replacing an incumbent, or augmenting it? Do you put the CMO’s team in the lead role of the narrative, or do you appear to route around them? Do you give IT an ownership story they can take to governance, or do you hand them an operational mystery? None of this is optics. It is the structure of the position itself. Positioning in healthtech is not just about the buyer’s head. It is about the org chart the buyer has to navigate.

Six.Proof is the foundation, not decoration.

Health systems buy on evidence, not narrative. This is the last place generic positioning advice breaks down. In venture-backed consumer and SMB markets, a crisp narrative with a clean design system can carry you a long way. In provider markets, narrative gets you to the first meeting. Evidence closes the deal. Named peer logos, IDN, academic medical center, regional system, carry more weight than any amount of copy. Quantified before-and-after outcomes carry more weight than any case study prose. Documented workflow specifics, implementation timelines, and security artifacts ready for review are not closing tools; they are qualifying tools. Without them, the right conversation does not happen.

This has a positioning consequence most founders miss: the proof story has to be designed into the position, not bolted on after the fact. If your positioning implies outcomes you cannot yet prove, the deal either does not close or it closes at a lower price. If your positioning is narrow enough that your first three customers can produce clean, quantified, forwardable outcomes, that becomes the wedge for the next fifteen. Beachhead before expansion is not a go-to-market tactic. It is a positioning requirement.

Seven.The diagnostic.

Run any positioning statement through these quick diagnostic questions. If the answers are not crisp, the positioning will not hold.

1. Who signs the contract, and what budget funds it?
2. What system of control are you inside, dependent on, or replacing?
3. What metric moves this buyer this quarter?
4. What proof makes this safe enough to buy?
5. What do you explicitly exclude, and who is this not for?
6. What political friction does this create internally, and how is it neutralized?
7. What platform could bundle you out of existence, and what is your survival logic?

Most healthtech positioning statements I see fail three or four of these. The founder knows the product cold. The positioning was written for a homepage and never pressure-tested against the seventh floor of a health system. The gap between those two things is where pipeline goes to die.

If you cannot answer these crisply, you do not have a positioning problem you can solve alone. That is what the Sprint is for.